KYMERA THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Liabilities
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Other Noncurrent Liabilities of $18.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-02-26
- KYMERA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $18.00K.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$310.00K.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$28.00K, a 110.89% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $257.00K, a 198.84% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|
| 2025-12-31 | $18.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | -$310.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | -$28.00K 10-K · filed 2026-02-26 |
| 2022-12-31 | $257.00K 10-K · filed 2025-02-27 |
| 2021-12-31 | $86.00K 10-K · filed 2024-02-22 |
| 2020-12-31 | $205.00K 10-K · filed 2023-02-23 |
| 2019-12-31 | -$7.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |